Methods and nucleic acids for analyses of cellular proliferative disorders

Abstract

The invention provides methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among liver cell proliferative disorders or for detecting, or for detecting and distinguishing between or among colorectal cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients.

1 . A method for detecting and/or classifying cell proliferative disorders in a subject, comprising determining the expression levels of Septin 9 in a biological sample isolated from said subject, wherein underexpression and/or CpG methylation is indicative of the presence or class of said disorder. 
     
     
         2 . The method of  claim 1 , wherein a neoplastic cell proliferative disorder is distinguished from a benign cell proliferative disorder, said method characterized in that underexpression and/or the presence of CpG methylation is indicative of the presence of a neoplastic cell proliferative disorder, and the absence thereof is indicative of the presence of a benign cell proliferative disorder. 
     
     
         3 . The method of  claim 1 , wherein said cell proliferative disorder is cancer. 
     
     
         4 . The method of  claim 3 , wherein said cell proliferative disorder is hepatocellular or colorectal carcinoma. 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . The method of  claim 1 , wherein said expression is determined by detecting the presence or absence of CpG methylation within said gene, wherein the presence of methylation indicates the presence of a cell proliferative disorder. 
     
     
         8 . The method of  claim 1 , comprising contacting genomic DNA isolated from a biological sample obtained from said subject with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one target region of the genomic DNA, wherein the target region comprises, or hybridizes under stringent conditions to a sequence of at least 16 contiguous nucleotides of at least one sequence selected from the group consisting of SEQ ID NOS:1 to SEQ ID NO:3, respectively, wherein said contiguous nucleotides comprise at least one CpG dinucleotide sequence, and whereby detecting and/or classifying cell proliferative disorders is, at least in part, afforded. 
     
     
         9 . The method of  claim 8 , comprising:
 a) extracting or otherwise isolating genomic DNA from a biological sample obtained from the subject;   b) treating the genomic DNA of a), or a fragment thereof, with one or more reagents to convert cytosine bases that are unmethylated in the 5-position thereof to uracil or to another base that is detectably dissimilar to cytosine in terms of hybridization properties;   c) contacting the treated genomic DNA, or the treated fragment thereof, with an amplification enzyme and at least one primer comprising a contiguous sequence of at least 9 nucleotides that is complementary to, or hybridizes under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NOS:4 to SEQ ID NO:15, and complements thereof, wherein the treated genomic DNA or the fragment thereof is either amplified to produce at least one amplificate, or is not amplified; and   d) determining, based on a presence or absence of, or on a property of said amplificate, the methylation state or level of at least one CpG dinucleotide of a sequence selected from the group consisting SEQ ID NOS:1 to SEQ ID NO:3, or an average, or a value reflecting an average methylation state or level of a plurality of CpG dinucleotides of a sequence selected from the groups consisting of SEQ ID NOS:1 to SEQ ID NO:3, whereby at least one of detecting and classifying cellular proliferative disorders is, at least in part, afforded.   
     
     
         10 . The method of  claim 9 , wherein treating the genomic DNA, or the fragment thereof in b), comprises use of a reagent selected from the group comprising of bisulfate, hydrogen sulfite, disulfite, and combinations thereof. 
     
     
         11 . The method of  claim 9 , wherein contacting or amplifying in c) comprises use of at least one method selected from the group comprising: use of a heat-resistant DNA polymerase as the amplification enzyme; use of a polymerase lacking 5′-3′ exonuclease activity; use of a polymerase chain reaction (PCR); generation of an amplificate nucleic acid molecule carrying a detectable label. 
     
     
         12 . The method of  claim 1 , wherein the biological sample obtained from the subject is selected from the group comprising cell lines, histological slides, biopsies, paraffin-embedded tissue, body fluids, stool, colonic effluent, urine, blood plasma, blood serum, whole blood, isolated blood cells, cells isolated from the blood, and combinations thereof. 
     
     
         13 . The method of  claim 10 , further comprising, in step d), the use of at least one nucleic acid molecule or peptide nucleic acid molecule comprising in each case a contiguous sequence at least 9 nucleotides in length that is complementary to, or hybridizes under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NOS:4 to SEQ ID NO:15, and complements thereof, wherein said nucleic acid molecule or peptide nucleic acid molecule suppresses amplification of the nucleic acid to which it is hybridized. 
     
     
         14 . The method of  claim 10 , wherein determining in d) comprises hybridization of at least one nucleic acid molecule or peptide nucleic acid molecule in each case comprising a contiguous sequence at least 9 nucleotides in length that is complementary to, or hybridizes under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NOS:4 to SEQ ID NO:15, and complements thereof. 
     
     
         15 . The method of  claim 14 , wherein at least one such hybridizing nucleic acid molecule or peptide nucleic acid molecule is bound to a solid phase. 
     
     
         16 . The method of  claim 15 , further comprising extending at least one such hybridized nucleic acid molecule by at least one nucleotide base. 
     
     
         17 . The method of  claim 10 , wherein determining in d), comprises sequencing of the amplificate. 
     
     
         18 . The method of  claim 10 , wherein contacting or amplifying in c), comprises use of methylation-specific primers. 
     
     
         19 - 21 . (canceled) 
     
     
         22 . A nucleic acid, comprising at least 16 contiguous nucleotides of a treated genomic DNA sequence selected from the group consisting of SEQ ID NOS:4 to SEQ ID NO:15, and sequences complementary thereto, wherein the treatment is suitable to convert at least one unmethylated cytosine base of the genomic DNA sequence to uracil or another base that is detectably dissimilar to cytosine in terms of hybridization. 
     
     
         23 . (canceled) 
     
     
         24 . The nucleic acid of  claim 22 , wherein the contiguous base sequence comprises at least one CpG, TpG or CpA dinucleotide sequence. 
     
     
         25 - 27 . (canceled) 
     
     
         28 . A kit suitable for performing the method according to  claim 9 , comprising: (a) a bisulfite reagent; (b) a container suitable for containing the said bisulfite reagent and the biological sample of the patient; and (c) at least one set of oligonucleotides containing two oligonucleotides whose sequences in each case are identical, are complementary, or hybridize under stringent or highly stringent conditions to a 9 or more preferably 18 base long segment of a sequence selected from SEQ ID NOS:4 to SEQ ID NO:15. 
     
     
         29 - 31 . (canceled)